Extremely significant negative changes in Editas Medicine Inc (NASDAQ: EDIT) investment behavior have recently occurred: its longer term price trend turned down, and its shorter term price trend turned down.
Recent meaningful negative changes in fundamentals have affected Editas Medicine Inc (NASDAQ: EDIT): the stock’s power rating fell below 50, and significant quarterly earnings deceleration occurred.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, EDIT is expected to continue to be Value Creation neutral.
Editas Medicine has a current Value Trend Rating of F (Lowest Rating). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Editas Medicine has a neutral Power Rating of 46 but a poor Appreciation Score of 16, producing the Lowest Value Trend Rating.
Recent Price Action
On 3/12/24, Editas Medicine Inc (NASDAQ: EDIT) stock declined by -4.3%, closing at $8.61. However, this decline was accompanied by below average trading volume at 82% of normal. The stock has performed in line with the market over the last nine months and has declined -13.2% during the last week.
Be the first to comment